Robert Bindert Huizinga, EVP of Research at Aurinia Pharmaceuticals Inc. (AUPH), sold 65,000 shares at $24.05 ($1.6M) on 2021-09-21, disclosed to the SEC on 2021-09-22.
Open-market sale of $1.6M AUPH by EVP of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.66 | 5,364 | $127K | 8.1% |
| 2 | $23.66 | 5,364 | $127K | 8.1% |
| 3 | $24.05 | 27,136 | $653K | 41.9% |
| 4 | $24.05 | 27,136 | $653K | 41.9% |
| Total | $23.99 avg | 65,000 | $1.6M | 100% |
| Filing → |
| AUPH | SELL | 2021-09-14 | $885K | — | Filing → |
| AUPH | SELL | 2021-09-08 | $92K | — | Filing → |